{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:30:20Z","timestamp":1782552620506,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database between 2019 Q1 and 2023 Q4. Reporting odds ratio (ROR), proportional reporting ratio (PRR), and multi-item gamma Poisson shrinker (MGPS) were performed to detect risk signals from the FAERS data to identify potential ESK-NS\u2013AEs associations. A total of 14,606 reports on AEs with ESK-NS as the primary suspected drug were analyzed. A total of 518 preferred terms signals and 25 system organ classes mainly concentrated in psychiatric disorders (33.20%), nervous system disorders (16.67%), general disorders and administration site conditions (14.21%), and others were obtained. Notably, dissociation (<jats:italic>n<\/jats:italic> = 1,093, ROR 2,257.80, PRR 899.64, EBGM 876.86) exhibited highest occurrence rates and signal intensity. Moreover, uncommon but significantly strong AEs signals, such as hand\u2013eye coordination impaired, feeling guilty, and feelings of worthlessness, were observed. Additionally, dissociative disorder (<jats:italic>n<\/jats:italic> = 57, ROR 510.92, PRR 506.70, EBGM 386.60) and sedation (<jats:italic>n<\/jats:italic> = 688, ROR 172.68, PRR 155.53, and EBGM 142.05) both presented strong AE signals, and the former is not recorded in the Summary of Product Characteristics (SmPC). In clinical applications, close attention should be paid to the psychiatric disorders and nervous system disorders, especially dissociation. Meanwhile, clinical professionals should be alert for the occurrence of AEs signals not mentioned in the SmPC and take preventive measures to ensure the safety of clinical use.<\/jats:p>","DOI":"10.3389\/fphar.2024.1414703","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:47:47Z","timestamp":1718340467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruixue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"B1","volume-title":"Efficacy, safety, and risk-benefit profile of new drug application (NDA) 211243, esketamine 28 mg single-use nasal spray device","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","article-title":"A word to the wise about intranasal esketamine","volume":"176","author":"AlanSchatzberg","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","article-title":"Treatment-resistant depression and suicidality","volume":"235","author":"Bergfeld","year":"2018","journal-title":"J. Affect. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"CarlaCanuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40263-023-01026-3","article-title":"Efficacy and safety of esketamine nasal spray in patients with treatment-resistant depression who completed a second induction period: analysis of the ongoing SUSTAIN-3 study","volume":"37","author":"Castro","year":"2023","journal-title":"CNS Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1747-597X-9-39","article-title":"Gender differences in subjective discontinuation symptoms associated with ketamine use","volume":"9","author":"Chen","year":"2014","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.forsciint.2004.08.023","article-title":"An epidemiological study on alcohol\/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000","volume":"153","author":"Cheng","year":"2005","journal-title":"Forensic Sci. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(19)30292-5","article-title":"US Food and Drug Administration approval of esketamine and brexanolone","volume":"6","author":"Cristea","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/bcp.14015","article-title":"Susceptibility to adverse drug reactions","volume":"85","author":"Ferner","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"19m13191","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2020","journal-title":"Psychotherapy Psychosomatics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"849758","DOI":"10.3389\/fphar.2022.849758","article-title":"Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B15","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.9758\/cpn.2022.20.1.70","article-title":"Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression-an asian sub-group analysis from the SUSTAIN-2 study","volume":"20","author":"Jeon","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2147\/dddt.s285862","article-title":"Repeated doses of ketamine affect the infant rat urogenital system","volume":"15","author":"Kas\u0131kara","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression \u2014 first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.9758\/cpn.22.1034","article-title":"The role of glutamate underlying treatment-resistant depression","volume":"21","author":"Kim","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/16066350801983749","article-title":"Towards an explanation of subjective ketamine experiences among Young injection drug users","volume":"16","author":"Lankenau","year":"2008","journal-title":"Addict. Res. Theory"},{"key":"B22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2215-0366(21)00251-0","article-title":"Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study","volume":"8","author":"Lu","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"B23","first-page":"54","article-title":"Esketamine nasal spray (Spravato) for treatment-resistant depression","volume":"61","year":"2019","journal-title":"Med. Lett. drugs Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatric Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2042098620937899","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/JCP.0b013e3181612cdc","article-title":"Trapped in the \"K-hole\": overview of deaths associated with ketamine misuse in the UK (1993-2006)","volume":"28","author":"Schifano","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"B29","unstructured":"Summary of product characteristics\n            SpravatoJ. C. l. I. l.\n          2019"},{"key":"B30","volume-title":"Approval package for Spravato nasal spray","author":"Titusville","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Vanina Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","article-title":"Gabapentin drug misuse signals: a pharmacovigilance assessment using the FDA adverse event reporting system","volume":"206","author":"Vickers-Smith","year":"2020","journal-title":"Drug Alcohol Dependence"},{"key":"B33","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. psychiatry"},{"key":"B34","volume-title":"Depression and other common mental disorders","year":"2017"},{"key":"B35","unstructured":"Mental health in China2024"},{"key":"B36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatry Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41386-023-01577-5","article-title":"Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study","volume":"48","author":"Zaki","year":"2023","journal-title":"Neuropsychopharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1414703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:47:56Z","timestamp":1718340476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1414703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":38,"alternative-id":["10.3389\/fphar.2024.1414703"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1414703","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"article-number":"1414703"}}